Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say

Semaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European Association for the Study of Obesity published in Nature Medicine.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MtGbVzl
via IFTTT